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Abstract
The fluorescent compounds rhodamine 123, LysoTracker Green DMD-26, mitoxantrone, and BODIPY-prazosin were
used with the antagonist fumitremorgin C (FTC) in order to develop functional assays for the half-transporter, MXR/BCRP/
ABCP1. A measure of FTC-inhibitable efflux was generated for each compound in a series of MXR-overexpressing drug-
selected cell lines and in ten unselected cell lines which were used to determine if the four fluorescent compounds were
sensitive enough to detect the low MXR levels found in drug-sensitive cell lines. FTC-inhibitable efflux of mitoxantrone and
prazosin was found in four of the ten cell lines, SF295, KM12, NCI-H460, and A549, and low but detectable levels of MXR
mRNA were also observed by Northern analysis in these cells. FTC-inhibitable mitoxantrone and prazosin efflux in both
selected and unselected cell lines was found to correlate well with MXR levels as determined by Northern blotting, r2 = 0.89
and r2 = 0.70 respectively. In contrast, rhodamine and LysoTracker were not able to reliably detect MXR. Cytotoxicity
assays performed on two of the four unselected cell lines confirmed increased sensitivity to mitoxantrone in the presence of
FTC. FTC was found to be a specific inhibitor of MXR, with half-maximal inhibition of MXR-associated ATPase activity at
1 WM FTC. Short term selections of the SF295, KM12, NCI-H460 and A549 cell lines in mitoxantrone resulted in a small but
measurable increase in MXR by both Northern blot and functional assay. These studies show that flow cytometric
measurement of FTC-inhibitable mitoxantrone or prazosin efflux is a sensitive and specific method for measuring the
function of the MXR half-transporter in both selected and unselected cell lines. ß 2001 Elsevier Science B.V. All rights
reserved.
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1. Introduction
In cancer cells, the multidrug resistance phenotype
is often associated with overexpression of members
of the ATP-binding cassette (ABC) transporter fam-
ily of proteins. P-glycoprotein (Pgp) and the multi-
drug resistance-associated protein (MRP) are two of
the most extensively studied ABC transporters and
have been shown to actively transport a wide variety
of cytotoxic agents [1,2]. More recently, an ABC
half-transporter protein, the mitoxantrone resistance
protein, MXR, was cloned from colon cells selected
in high levels of mitoxantrone [3]. Except for minor
amino acid di¡erences, MXR is identical to the
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breast cancer resistance protein (BCRP), which was
found to be highly overexpressed in breast cancer
cells selected in adriamycin in the presence of vera-
pamil [4] ; and to the placental ABC protein
(ABCP1) which was found by examination of ex-
pressed sequence tag databases [5]. MXR/BCRP/
ABCP1 confers high levels of resistance to mitoxan-
trone as well as to the anthracyclines, the camptothe-
cins, topotecan, and SN-38 [3,4,6^8]. Since MXR is a
half-transporter, it is thought that dimerization is
required for activity [9]. It has high homology with
the Drosophila white gene which encodes a half-
transporter involved in the transport of precursors
to eye pigment. The Human Gene Nomenclature
Committee has proposed that MXR/BCRP/ABCP1
be renamed ABCG2 (http://www.gene.ucl.ac.uk/
users/hester/abc.html).
The ability of ABC transporters to actively trans-
port compounds against a concentration gradient
across the cell membrane has allowed the develop-
ment of a number of functional assays to measure
the level and function of transporter present. The
e¥ux of £uorescent compounds from cells expressing
ABC proteins can be quickly and easily measured by
£ow cytometry. Many £uorescent compounds have
been used to characterize Pgp, although rhodamine
123 seems to be one of the most widely used [10,11].
When used in conjunction with a Pgp blocker such as
cyclosporin A or PSC 833, rhodamine 123 e¥ux has
been shown to correlate well with Pgp expression in
unselected cell lines [12]. MRP-mediated transport in
cells has been measured similarly by using calcein
AM [13,14]. These assays have been most widely de-
veloped in leukemia where functional measures of
Pgp and MRP have correlated well with mRNA ex-
pression levels [15,16].
A £uorescent substrate speci¢c for MXR alone has
yet to be identi¢ed. Rhodamine 123 e¥ux has been
previously shown in cell lines which express MXR,
and cells transfected with the BCRP gene have been
shown to transport rhodamine as well [5] ; however,
it is not known how sensitive rhodamine 123 is in
detecting low levels of MXR. A marked decrease in
mitoxantrone accumulation has also been shown in
cells expressing high levels of MXR [3,4,8]. A £uo-
rescent aza-anthrapyrazole, BBR 3390, was also re-
cently shown to be a substrate of BCRP [17]. In a
search for speci¢c substrates for MXR, we have also
noted decreased accumulation of the acidic organelle
probe LysoTracker Green DND-26, and BODIPY-
prazosin in MXR-overexpressing cells [8]. Recently,
fumitremorgin C (FTC) [18,19], an extract of Asper-
gillus fumigatus, and GF120918 [20], a compound
¢rst developed as a Pgp inhibitor, have been shown
to inhibit MXR. Based on other £ow cytometry
models used for detection of Pgp and MRP, it should
be possible to develop a functional assay for MXR.
We sought to develop a £ow cytometric assay
which would accurately re£ect the high levels found
in drug selected cell lines, as well as be sensitive
enough to detect low levels of MXR such as would
be found in unselected cell lines and clinical samples.
We assessed the ability of four £uorescent com-
pounds ^ rhodamine 123 (rhodamine), LysoTracker
Green DND-26 (LysoTracker), BODIPY-prazosin
(prazosin), and mitoxantrone ^ used in combination
with FTC to detect MXR in unselected cell lines as
well as several drug-selected cell lines expressing
varying amounts of MXR. Additionally, we wished
to determine if e¥ux of these £uorescent compounds
could be correlated with MXR expression at the
RNA level.
2. Materials and methods
Fumitremorgin C was synthesized by Thomas
McCloud, Developmental Therapeutics Program,
Natural Products Extraction Laboratory, National
Institutes of Health (Bethesda, MD). Mitoxantrone
and rhodamine 123 were purchased from Sigma (St.
Louis, MO, USA). BODIPY-prazosin and Lyso-
Tracker Green DMD-26 were obtained from Molec-
ular Probes (Eugene, OR, USA).
2.1. Cell lines
The cell lines comprising the National Cancer In-
stitute Anticancer Drug Screen were obtained as de-
scribed previously [21]. The human colon carcinoma
cell line S1 and its MXR-overexpressing subline
S1-M1-3.2 were obtained from Dr. Lee M. Green-
berger (Wyeth-Ayerst) [18]. The S1-M1-80 subline
was generated in our lab by exposing the S1-M1-
3.2 cell line to increasing concentrations of mitoxan-
trone [3]. The S1-M1-3.2 and S1-M1-80 cell lines
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were maintained in 3.2 WM and 80 WM of mitoxan-
trone, respectively. The Pgp-overexpressing line S1-
B1-20 was also obtained from Dr. Greenberger and
was maintained in 20 WM bisantrene [22].
Several MXR-overexpressing MCF-7 derivative
cell lines were also used in our study. The MCF-7
AdVp3000 cell line was derived by stepwise selection
and was maintained in 3000 ng/ml adriamycin re-
spectively, in the presence of 5 Wg/ml verapamil ;
the MCF-7 AdVp10 cell line was an early selection
step maintained in 10 ng/ml adriamycin and 5 Wg/ml
verapamil [23]. The MCF-7 MX8 cells were selected
in a single step and maintained in 8 ng/ml mitoxan-
trone. The MCF-7 MX20, MX40, MX80 and
MX100 sublines were independently selected in our
laboratory in a stepwise manner. The sublines are
carried in 20, 40, 80 and 100 ng/ml mitoxantrone
respectively. The MRP-overexpressing MCF-7/VP
cell line was obtained from Dr. Kenneth Cowan
[24], and was maintained in 4 WM etoposide.
The drug screen cells as well as S1 and derivative
sublines were maintained in RPMI; MCF-7 cells and
resistant sublines were maintained in IMEM; and
both were supplemented with 10% fetal bovine se-
rum, 2 mM L-glutamine, 100 U/ml penicillin, and
100 Wg/ml streptomycin. Resistant cell lines were
maintained in the selecting drug at the indicated con-
centrations and all cells were kept at 37‡C in 5%
CO2.
2.2. Microsomal membrane preparation
Microsomal membranes were prepared as previ-
ously described [25]. Brie£y, cells were washed with
PBS before being resuspended in 10 ml lysis bu¡er
(HEPES-Tris, 10 mM; EDTA, 5 mM; EGTA,
5 mM; dithiothreitol, 2 mM; pH 7.4) containing
protease inhibitors (phenylmethylsulfonyl £uoride,
2 mM; aprotinin, 5 Wg/ml; pepstatin, 10 Wg/ml; leu-
peptin, 10 Wg/ml). This and all subsequent steps were
performed at 4‡C. Cells were lysed by nitrogen cav-
itation (Parr Instrument, Moline, IL, USA) at
1200 psi for 20 min. Nuclei were sedimented by cen-
trifugation at 300Ug for 10 min, mitochondria were
removed by centrifugation at 4000Ug for 10 min and
in a ¢nal centrifugation (45 000Ug, 60 min), the mi-
crosomal fraction was sedimented. The pellet was
resuspended in 1 ml of lysis bu¡er and homogenized
by aspiration ten times through a 27 gauge syringe.
Aliquots of 150 Wl (containing 1^2 mg protein/ml)
were stored at 380‡C until analysis.
2.3. ATPase assay
MXR-associated ATPase activity was determined
according to Borgnia et al. [26], by quantitating the
release of inorganic phosphate from ATP, using a
sensitive, colorimetric assay originally described by
Chi¥et et al. [27] and later modi¢ed by Doige et
al. [28]. The microsomes were thawed on ice before
diluting to a protein concentration of 20 Wg/ml in ice-
cold ATPase assay medium (ATP, 3 mM; KCl,
50 mM; MgSO4, 2.5 mM; dithiothreitol, 3 mM;
Tris-HCl, 25 mM; pH 7.0) containing 0.5 mM
EGTA (to inhibit Ca-ATPases), 2 mM ouabain (to
inhibit the (Na+K)-ATPase), and 3 mM azide (to
inhibit mitochondrial ATPase). Each series of experi-
ments was carried out in a 96-well microtiter plate,
with reaction volumes of 50 Wl/well corresponding to
1 Wg protein/well. Incubation with FTC at various
concentrations was started by transferring the plate
from ice to 37‡C for 1 h, and terminated by addition
of 200 Wl ice-cold stopping medium (ammonium
molybdate, 0.2% (w/v); sulfuric acid, 1.3% (v/v);
SDS, 0.9% (w/v); trichloroacetic acid, 2.3% (w/v);
freshly prepared ascorbic acid, 1% (w/v)) to each
well. After 30 min incubation at room temperature,
the released phosphate was quantitated colorimetri-
cally in a microplate reader (Bio-Tek Instruments,
VT, USA) at 620 nm. Background and control ex-
periments with ATPase assay bu¡er alone, samples
incubated on ice, and samples incubated with 500
WM vanadate (inhibiting the MXR ATPase) were
obtained in parallel and subtracted from the mea-
surements.
2.4. Quantitative PCR and Northern blot
RNA was prepared using RNA STAT-60 accord-
ing to the manufacturer’s instructions (Tel-Test,
Friendswood, TX, USA). Northern blotting was per-
formed as previously described [3]. Quantitative PCR
was performed as previously described [29] using the
following primers: 5P primer: 5P-TGC CCA GGA
CTC AAT GCA AC-3P ; 3P primer: 5P-GAC TGA
AGG GCT ACT AAC C-3P.
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Autoradiograms or ethidium-stained gels were
captured and quantitated using the IP Lab Gel pro-
gram v 2.2 (Scanalytics, Fairfax, VA, USA).
2.5. E¥ux assays
The e¥ux assays were based on those previously
described with minor modi¢cations [12]. Suspensions
of log phase cells were obtained by trypsinization
and transferred to round-bottom 96-well plates.
The cells were resuspended in complete medium
alone (phenol red-free IMEM with 10% FCS), or
complete medium containing the desired £uorescent
compound (0.5 Wg/ml rhodamine 123, 100 nM Lyso-
Tracker Green DMD-26, 250 nM BODIPY-prazo-
sin, or 20 WM mitoxantrone) with or without 10 WM
FTC and incubated at 37‡C in 5% CO2 for 30 min.
Cells in complete medium alone yielded the Blank
Fig. 1. Functional assay for MXR expression in selected cell lines. E¥ux assays were performed with the four £uorescent compounds
in each of the selected cell lines. Representative histograms are shown for four of the selected cell lines. Cells were incubated for
30 min with medium alone (heavy solid line); incubated with 0.5 Wg/ml rhodamine, 100 nM LysoTracker, 250 nM prazosin, or 20 WM
mitoxantrone, washed, then allowed to incubate for 60 min in medium alone (thin solid line); or incubated with 0.5 Wg/ml rhodamine,
100 nM LysoTracker, 250 nM prazosin, or 20 WM mitoxantrone in the presence of 10 WM FTC, washed, then allowed to incubate for
60 min in medium containing 10 WM FTC (dotted line). For the S1-B1-20 cell line, cells were additionally incubated with 0.5 Wg/ml
rhodamine, 100 nM LysoTracker, 250 nM prazosin, or 20 WM mitoxantrone in the presence of 3 Wg/ml PSC 833, washed, then al-
lowed to incubate for 60 min in medium containing 3 Wg/ml PSC 833 (dashed line).
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histogram which is a measure of cell auto£uores-
cence, while cells in complete medium with a £uores-
cent compound or complete medium with a £uores-
cent compound and FTC generated the Control and
FTC histograms, respectively. After the 30 min in-
cubation period, the cells were washed with ice-cold
complete medium and either placed on ice in the
dark, or were resuspended in complete medium, con-
tinuing with or without 10 WM FTC and allowed to
incubate for 1 additional hour at 37‡C in 5% CO2.
The E¥ux histogram was generated from cells which
were incubated 30 min with a £uorescent compound
and then allowed to e¥ux for 1 h in complete me-
dium alone; the FTC/E¥ux histogram was obtained
from cells which were incubated 30 min with a £uo-
rescent compound and FTC, then incubated in com-
plete medium and FTC for 1 h. The cells were then
washed in cold DPBS and placed on ice. A FACSort
£ow cytometer with a 488 nm argon laser and 530
nm bandpass ¢lter was used to detect rhodamine,
LysoTracker, and prazosin £uorescence, while a
FACSCalibur £ow cytometer equipped with a 635
nm red diode laser and 670 nm bandpass ¢lter was
used to detect mitoxantrone £uorescence. At least
10 000 events were collected. Debris was eliminated
by gating on forward versus side scatter and dead
cells were excluded based on propidium iodide stain-
ing. The mean channel number for each histogram
was used as the measure of £uorescence for calcula-
tion of e¥ux values.
2.6. Cytotoxicity assay
The cytotoxicity assays were performed using the
sulforhodamine method previously described [30].
Brie£y, cells were plated in £at-bottom 96-well plates
at a density of 2000 cells per well and allowed to
attach for 24 h at 37‡C in 5% CO2. Mitoxantrone
at various concentrations with or without FTC at a
concentration of 5 WM was added to the cells and
allowed to incubate at 37‡C in 5% CO2 for 96 h.
After incubation, the cells were ¢xed in 50% TCA
and stained with sulforhodamine B solution (0.4%
sulforhodamine B w/v in 1% acetic acid). Optical
densities were read on a Bio-Rad plate reader at an
absorbance of 540 nm. Each concentration was
tested in triplicate and controls were done in repli-
cates of eight.
Fig. 2. Expression of MXR in parental and drug-selected cell lines. Northern blot analysis of MXR expression in (A) drug-selected
cell lines and (B) the 11 unselected cell lines was performed as outlined in Section 2.
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3. Results
3.1. Functional assay for MXR in selected cell lines
We ¢rst examined the intracellular £uorescence of
four £uorescent compounds by £ow cytometry in a
series of multidrug-resistant cell lines. Previous stud-
ies by confocal microscopy had demonstrated re-
duced intracellular accumulation of mitoxantrone,
prazosin, LysoTracker and rhodamine, among
others, in two selected sublines with MXR overex-
pression [8]. Each cell line was tested at least twice
with each compound; histograms in four drug-se-
lected cell lines are shown in Fig. 1. Cells were in-
cubated, as described in Section 2, with or without
the addition of FTC during the accumulation period
and then washed and continued with or without FTC
for an e¥ux period. Data were collected following
both the accumulation period and the e¥ux period
and comparable results were obtained with both;
only the post-e¥ux histograms are presented in
Fig. 1. The di¡erence between the mean channel
number for the FTC/E¥ux histogram (dotted line)
and the E¥ux histogram (solid line) yielded the most
reproducible values. This di¡erence in mean channel
numbers was termed ‘FTC-inhibitable e¥ux’ and
was used in subsequent correlations with MXR ex-
pression. In the MXR-overexpressing MCF-7
AdVp3000 and S1-M1-80 cells, a high level of
FTC-inhibitable e¥ux is noted with all of the com-
pounds. In the MCF-7/MX8 cells, which overexpress
MXR at a slightly lower level, mitoxantrone and
prazosin e¥ux was detected, while e¥ux of Lyso-
Tracker and rhodamine was not. In the parental
cell line, S1, no e¥ux was noted, and in the parental
MCF-7 cells a slight but reproducible amount of
FTC-inhibitable mitoxantrone and prazosin e¥ux
was observed. In the Pgp-overexpressing line S1-
B1-20, the Pgp antagonist PSC 833 (dashed line)
was able to inhibit e¥ux of all of the compounds
except LysoTracker; however, there was no e¡ect
of FTC. Likewise, no FTC-inhibitable e¥ux was
noted in the MRP-overexpressing subline MCF-7/
VP with any of the compounds studied (data not
shown). There was signi¢cant quenching of Lyso-
Tracker which may account for the small values of
FTC-inhibitable LysoTracker e¥ux in some of the
cell lines.
3.2. MXR mRNA expression in selected and
unselected cell lines
With the aim of correlating MXR levels with the
functional assay, MXR mRNA expression was mea-
sured by Northern blot analysis in the selected cell
lines with the results presented in Fig. 2A. Extending
previous reports, high levels were found in S1-M1-80
and MCF-7 AdVp3000 cells. High levels were also
noted in MCF-7/MX100 cells, intermediate levels
Fig. 3. Functional assay for MXR expression in unselected cell
lines. E¥ux assays were carried out on the 11 unselected cell
lines with the four £uorescent compounds as outlined in Fig. 1:
heavy solid line, Blank; thin solid line, E¥ux; dotted line,
FTC/E¥ux.
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were found in MCF-7 MX8 and MCF-7 AdVp10
cells, a very low level was seen in MCF-7 parental
cells and no MXR was detected in S1 or S1-B1-20
cells.
Our next step was to determine whether any of the
£uorescent compounds would be sensitive enough to
detect low levels of MXR such as would be found in
unselected cell lines. MXR levels were determined by
quantitative PCR (data not shown) in 54 of the
60 cell lines which comprise the National Cancer In-
stitute Anticancer Drug Screen. From this initial
screening ten cell lines were identi¢ed that had
MXR mRNA levels above the mean, including
SF-295, M14, SN12C, KM12, HCC-2998, HT29,
HOP-62, NCI-H460, A549, and NCI-H23 cells.
One cell line without detectable MXR expression,
IGROV, was also included as a negative control. A
Northern analysis of these cell lines is shown in Fig.
2B. In the 11 drug screen cell lines, MXR expression
was detectable by Northern in SF295, KM12, NCI-
H460 and A549 cells. S1 parental and S1-M1-80 cells
are shown for comparison.
3.3. Functional assay for MXR in unselected cell lines
Functional assays with the four compounds were
performed in the 11 drug screen cell lines. Fig. 3
presents histograms for mitoxantrone and prazosin
for the SF295, KM12, NCI-H460, A549, M14, and
IGROV cell lines. A notable and reproducible di¡er-
ence in mean channel values for cells allowed to ef-
£ux in the presence or absence of FTC was seen with
Fig. 4. Correlation of MXR expression with e¥ux of the two £uorescent compounds. The di¡erence in mean channel number between
the FTC/E¥ux and E¥ux histograms for mitoxantrone and prazosin was calculated for each cell line studied and plotted against nor-
malized MXR expression values as determined by Northern blot in (A) all cell lines studied or (B) the 11 unselected cell lines alone.
BBAMEM 78082 28-5-01
R.W. Robey et al. / Biochimica et Biophysica Acta 1512 (2001) 171^182 177
mitoxantrone and prazosin in the unselected cell lines
SF295, KM12, NCI-H460 and A549, but not in the
remaining cell lines which is in agreement with MXR
mRNA expression levels in these cells.
3.4. Correlation of MXR expression with e¥ux of
£uorescent compounds
To determine whether the extent of FTC-inhibit-
able e¥ux could be related to MXR expression, the
di¡erence in mean channel numbers between the
FTC/E¥ux and E¥ux histograms was correlated
with MXR mRNA expression values obtained from
Northern blots from all drug-selected and unselected
cell lines shown in Fig. 2. When mitoxantrone e¥ux
was plotted against MXR expression in both selected
and unselected cell lines, a good correlation
(r2 = 0.89) was obtained; similar results were ob-
tained with prazosin e¥ux (r2 = 0.70) (Fig. 4A).
FTC-inhibitable LysoTracker and rhodamine did
Fig. 5. Sensitization of unselected cell lines to mitoxantrone by FTC. Cytotoxicity assays were performed using mitoxantrone alone
(E) or mitoxantrone in the presence of 5 WM FTC (b) on the NCI-H460, A549, SN12C, IGROV, MCF-7 cell lines. S1-M1-3.2 cells
are shown for comparison.
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not correlate well in the selected cell lines, and were
unable to detect low levels of MXR in the unselected
cells (data not shown). In fact, some of the lines with
high MXR levels did not exhibit any rhodamine ef-
£ux at all. As shown in Fig. 4B, FTC-inhibitable
mitoxantrone and prazosin e¥ux also correlated
well with MXR expression in the unselected cell lines
alone, with r2 = 0.77 and r2 = 0.76, respectively. Lyso-
Tracker and rhodamine were not able to detect the
low levels of MXR in these cells, r2 = 0.07 and
r2 = 0.03 respectively (data not shown).
3.5. Sensitization of unselected cell lines to
mitoxantrone by FTC
Since the £ow cytometry data showed that FTC
was able to increase mitoxantrone accumulation in
some of the unselected cell lines, the ability of FTC
to sensitize cells to mitoxantrone in a 4 day cytotox-
icity assay was evaluated. Cytotoxicity experiments
were performed on three cell lines with FTC-inhibit-
able mitoxantrone e¥ux, A549, NCI-H460 and
MCF-7, on one of the cell lines which showed no
FTC-reversible mitoxantrone e¥ux, SN12C, and on
the negative control cell line IGROV. As seen in Fig.
5, the NCI-H460, A549 and MCF-7 cell lines were
sensitized 3^4-fold to mitoxantrone. The SN12C cell
line showed no increased sensitivity to mitoxantrone
in the presence of FTC which is in agreement with
the mitoxantrone and prazosin e¥ux data. In the
negative control cell line, IGROV, no further sensi-
tization to mitoxantrone was seen. For comparison,
results with the S1-M1-3.2 cells are presented, with
FTC able to sensitize these cells 400-fold.
3.6. Kinetics of MXR inhibition by FTC
To evaluate the kinetics of the inhibition of MXR
by FTC, the e¡ects of FTC on ATPase activity in
membranes isolated from S1-M1-80 cells were
studied. As Fig. 6 demonstrates, FTC is able to in-
hibit MXR-associated ATPase activity, with a Ki, or
concentration of FTC required for half-maximal in-
hibition of MXR, of 1 WM. No e¡ect of FTC was
observed in membranes prepared from parental S1
cells (data not shown).
3.7. Upregulation of MXR in unselected cell lines
treated with mitoxantrone
To determine whether MXR could be upregulated
and thus detected more readily in unselected cells
which already express low levels of MXR, the four
cell lines showing the highest amount of mitoxan-
trone and prazosin e¥ux ^ SF295, KM12, NCI-
H460 and A549 ^ were incubated in 10 nM mitox-
antrone to develop the resistant sublines SF295
MX10, KM12 MX10, NCI-H460 MX10, and A549
MX10. Mitoxantrone e¥ux and MXR expression
were then assayed. As shown in Fig. 7A, a reproduc-
ible increase in FTC-reversible mitoxantrone e¥ux
is seen in three of the four mitoxantrone-resistant
sublines compared to the parental lines. Additional-
ly, MXR mRNA expression was upregulated in the
A549 MX10, NCI-H460, KM12 MX10, and SF295
MX10 cells relative to the MXR mRNA levels in the
parental lines as seen by the Northern blot in Fig.
7B. S1-M1-80 cells are shown as a positive control.
Fig. 6. FTC inhibits MXR-related ATPase activity. MXR ATP-
ase activity was measured at various concentrations of FTC in
microsomal membranes prepared from MXR-overexpressing
S1-M1-80 cells. The Ki, or concentration required for half-maxi-
mal inhibition of MXR-related ATPase activity, was found to
be 1 WM.
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4. Discussion
In the present study, £ow cytometric measurement
of FTC-inhibitable mitoxantrone or BODIPY-prazo-
sin e¥ux proved to be a sensitive and speci¢c method
for detecting MXR in both highly resistant, drug-
selected cell lines as well as unselected cell lines,
and correlated well with MXR expression as deter-
mined by Northern blot. When cytotoxicity assays
were performed with FTC on unselected cell lines
in which FTC was able to increase mitoxantrone
and prazosin accumulation, a 3-fold sensitization to
mitoxantrone was noted. FTC-inhibitable e¥ux of
mitoxantrone and prazosin was not seen in MDR
or MRP positive cell lines, suggesting that FTC
may be speci¢c for inhibiting MXR. Additionally,
the concentration of FTC required for half-maximal
inhibition of MXR-related ATPase activity, or Ki,
was determined to be 1 WM.
Our data are consistent with the ¢ndings of Ra-
bindran et al., who described increased FTC-induced
retention of [14C]mitoxantrone and enhanced mitox-
antrone cytotoxicity in S1-M1-3.2 cells which express
increased levels of the MXR protein [18]. Addition-
ally, FTC was shown to enhance retention of a £uo-
rescent MXR substrate, BBR 3390, in BCRP-trans-
fected MCF-7 cells [19].
As FTC-reversible mitoxantrone and prazosin ef-
£ux was detected in unselected cell lines, this method
could be adapted to clinical applications. A number
of £ow cytometric assays have been developed to
detect the multidrug resistance phenotype and have
been extensively used in the clinical setting where
often only a small sample volume can be obtained.
Flow cytometry-based assays are also advantageous
in that they provide functional as well as quantitative
information about the multidrug resistance proteins
present in a given sample. Rhodamine 123 in con-
junction with a Pgp blocker has been used in clinical
applications such as determining the e¡ectiveness of
Pgp blockers in patients [31,32] and has been used
e¡ectively as a measure of Pgp-mediated resistance in
leukemia [15,33]. Calcein-AM has also been used
with the Pgp blocker cyclosporin A and the MRP
blocker probenecid to quantify Pgp- and MRP-medi-
ated resistance in acute myeloid leukemia (AML)
samples [16]. It has been suggested that MXR may
be responsible for cyclosporin-resistant drug e¥ux
which is not due to overexpression of Pgp, MRP
or LRP in AML [33,34]. Further, blast cells from
acute leukemia patients have recently been shown
to express detectable levels of MXR [35]. The studies
presented here thus form the basis for functional
detection of MXR in clinical samples.
One interesting ¢nding of the present study was
Fig. 7. Increased mitoxantrone e¥ux in mitoxantrone-selected
cells. (A) The four drug screen cell lines having the highest
amount of mitoxantrone e¥ux ^ A549, NIH-H460, KM12 and
SF295 ^ were incubated in 10 nM mitoxantrone to generate the
resistant sublines A549 MX10, NIH-H460 MX10, KM12
MX10, and SF295 MX10. The mitoxantrone e¥ux assay was
performed as outlined in Fig. 1: heavy solid line, Blank; thin
solid line, E¥ux; dotted line, FTC/E¥ux. (B) Northern blot
analysis of the parental and mitoxantrone-selected drug screen
cell lines. MXR-overexpressing S1-M1-80 cells are shown as a
positive control.
BBAMEM 78082 28-5-01
R.W. Robey et al. / Biochimica et Biophysica Acta 1512 (2001) 171^182180
that rhodamine and LysoTracker e¥ux did not cor-
relate well with MXR levels. In fact, some cell lines
with very high levels of MXR did not display rhod-
amine e¥ux. This ¢nding was surprising, since pre-
vious studies in our laboratory suggested that rhod-
amine 123 was a substrate for MXR [8]. Several
potential explanations are possible. First, we noted
quenching of the LysoTracker in many of the cell
lines tested. Second, di¡ering substrate speci¢cities
could result from di¡erent dimerization partners,
since MXR is a half-transporter and is thought to
dimerize for activity. Di¡erent partners confer di¡er-
ent substrate speci¢cities in the case of the Drosophila
white gene product. When the white gene product
complexes with the scarlet gene product, tryptophan
is transported; when it complexes with the brown
gene product, guanine is transported [9]. Third, poly-
morphisms or mutations in MXR could result in
di¡ering a⁄nities for substrates. Polymorphisms in
the rat tap gene result in di¡ering substrate speci¢c-
ities [36], and a splice variant of the human Tap2
gene, Tap2iso, was recently shown to encode for a
protein having peptide presentation patterns di¡erent
from the normal Tap2 gene product [37]. Acquired
mutations in Pgp have also been shown a¡ect cross-
resistance patterns in multidrug-resistant cells [38].
Recent studies in our laboratory suggest that amino
acid variation at position 482 between the various
published sequences for MXR correlates with the
ability of the protein to e¥ux rhodamine.
We have shown that cells which express low en-
dogenous levels of MXR are able to upregulate
MXR when exposed to relatively low levels of mitox-
antrone. A topotecan-resistant ovarian cancer cell
line was reported to have reduced topotecan accumu-
lation [39] and was found to overexpress MXR [40].
Recently, lung cancer cells exposed to SN-38 were
also shown to overexpress MXR [6]. These data
would suggest that MXR is an important mechanism
of resistance in some models, and may explain drug
resistance in mitoxantrone- or topotecan-resistant tu-
mors which test negative for Pgp. Studies are cur-
rently underway to determine MXR expression in
refractory tumors.
In conclusion, MXR appears to be an important
new ABC transporter, and is expressed in unselected
cells as well as in drug-selected cell lines. While its
clinical relevance has yet to be determined, the diver-
sity of its substrates and the high levels of cross-re-
sistance which MXR can confer suggest it ought to
be vigorously pursued.
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